Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease

@article{Cazzola2005UltraL,
  title={Ultra long-acting $\beta$2-agonists in development for asthma and chronic obstructive pulmonary disease},
  author={Mario Cazzola and Maria Gabriella Matera and Jan L{\"o}tvall},
  journal={Expert Opinion on Investigational Drugs},
  year={2005},
  volume={14},
  pages={775 - 783}
}
After the discovery of formoterol and salmeterol, new candidates for long-acting β2-adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once-daily β2-adrenoceptor agonists such as arformoterol, carmoterol, indacaterol, GSK-159797, GSK-597901, 159802, 642444 and 678007 are under development for the treatment of asthma and chronic obstructive pulmonary disease. The majority of these compounds are (R,R)-isomers in order to control desensitisation and accumulation… 
ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
TLDR
It is plausible that once-daily dose administration of an LABA will lead to increased convenience for patients, which may also lead to enhancement of adherence, and may have advantages leading to improved overall clinical outcomes in patients with asthma and COPD.
Ultra-Long-Acting β2-Adrenoceptor Agonists
TLDR
It is plausible that once-daily dose administration of an LABA will lead to increased convenience for patients, which may also lead to enhancement of adherence, and may have advantages leading to improved overall clinical outcomes in patients with asthma and COPD.
Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD
TLDR
Newly developed ultra-LABAs are focused on, describing currently available evidence of their clinical effect and safety, their comparison relative to older long-acting β2-agonists, and their potential niche in the maintenance treatment of COPD.
Novel bronchodilators in asthma
TLDR
It is likely that the once-daily dosing of a bronchodilator would be a significant convenience and probably a compliance-enhancing advantage, leading to improved overall clinical outcomes in patients with asthma.
Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
TLDR
This article reviews both clinically approved ULABA’s and ULABAs in development and describes how these agents are being combined with antimuscarinic agents and corticosteroids as dual and triple agent treatments that are being tested for clinical use and efficacy.
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
TLDR
The results from the ongoing large TOviTO Phase III trial program have documented the efficacy and safety of olodaterol/tiotropium fixed-dose combination as maintenance therapy in patients with moderate to very severe COPD.
β2‐adrenoceptor agonists: current and future direction
TLDR
It is likely that the once‐daily dosing of a bronchodilator would be a significant convenience and probably a compliance‐enhancing advantage, leading to improved overall clinical outcomes.
Review: Safety of long-acting β2 -agonists in the treatment of asthma
TLDR
Despite all of the concerns raised by the SMART, inhaled β2-agonists remain the most effective bronchodilators available for the immediate relief of asthma symptoms and, as such, remain an important component of asthma management.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
The pursuit of precision pharmaceuticals: divergent effects of beta2 agonist isomers.
TLDR
Airway hyperresponsiveness could diminish the capacity of beta agonists to protect from or result in paradoxical bronchospasm and there effects of racemic salbutamol, and the S isomer might cause hyper-responsiveness and potential airway inflammation.
Airway Subsensitivity with Long-Acting β2-Agonists
TLDR
The subsensitivity to bronchoprotection may be of clinical relevance in terms of patients who are inadvertently exposed to indirect bronchoconstrictor stimuli such as allergens or exercise, suggesting that long-acting β2-agonists should not be taken on a regular basis for this particular indication.
The role of long-acting bronchodilators in the management of stable COPD.
TLDR
All three long-acting bronchodilators in COPD were found to effectively improve lung function; however, they differed in their effects on outcomes other than Bronchodilation, with salmeterol demonstrating inconsistent efficacy compared with placebo in preventing exacerbations and improving health status.
Some pharmacodynamic aspects on long-acting β-adrenoceptor agonists
Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
TLDR
Data show that salmeterol is a partial agonist on the beta2-receptor in relation to formoterol in human airways in vivo, and further studies are required to document the clinical consequences of this finding, for example in severe asthmatic patients.
The asthma-like pharmacology and toxicology of (S)-isomers of β agonists☆☆☆
Beta-adrenoceptor agonists and asthma--100 years of development.
  • B. Waldeck
  • Medicine, Biology
    European journal of pharmacology
  • 2002
The effect of formoterol over 24 h in patients with asthma: the role of enantiomers.
...
1
2
3
4
5
...